"Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).
| Descriptor ID |
D011480
|
| MeSH Number(s) |
D27.505.519.389.745
|
| Concept/Terms |
Protease Inhibitors- Protease Inhibitors
- Inhibitors, Protease
- Endopeptidase Inhibitors
- Inhibitors, Endopeptidase
- Protease Inhibitor
- Inhibitor, Protease
- Peptide Hydrolase Inhibitors
- Hydrolase Inhibitors, Peptide
- Inhibitors, Peptide Hydrolase
- Peptide Peptidohydrolase Inhibitors
- Inhibitors, Peptide Peptidohydrolase
- Peptidohydrolase Inhibitors, Peptide
- Protease Antagonists
- Antagonists, Protease
- Antiproteases
- Peptidase Inhibitors
- Inhibitors, Peptidase
|
Below are MeSH descriptors whose meaning is more general than "Protease Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protease Inhibitors".
This graph shows the total number of publications written about "Protease Inhibitors" by people in this website by year, and whether "Protease Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 4 | 4 |
| 1998 | 0 | 3 | 3 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 3 | 3 |
| 2004 | 3 | 1 | 4 |
| 2005 | 0 | 1 | 1 |
| 2007 | 4 | 0 | 4 |
| 2008 | 1 | 2 | 3 |
| 2009 | 3 | 1 | 4 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 1 | 2 |
| 2014 | 2 | 2 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protease Inhibitors" by people in Profiles.
-
Discovery of Thioether-Cyclized Macrocyclic Covalent Inhibitors by mRNA Display. J Am Chem Soc. 2024 Aug 28; 146(34):24053-24060.
-
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. Eur J Cancer. 2024 Sep; 209:114236.
-
Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules. 2023 Sep 15; 28(18).
-
Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach. Bioorg Med Chem. 2021 10 01; 47:116393.
-
Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021 06 10; 184(12):3163-3177.e21.
-
Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics. Mol Neurobiol. 2020 Oct; 57(10):4106-4116.
-
Echocardiographic evaluation of the effects of sacubitril-valsartan on vascular properties in heart failure patients. Int J Cardiovasc Imaging. 2020 Feb; 36(2):271-278.
-
A system for the continuous directed evolution of proteases rapidly reveals drug-resistance mutations. Nat Commun. 2014 Oct 30; 5:5352.
-
Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase. Proc Natl Acad Sci U S A. 2014 Sep 16; 111(37):13517-22.
-
Interferon-combination strategies for the treatment of chronic hepatitis C. Semin Liver Dis. 2014 Feb; 34(1):30-6.